BEAM vs CRSP: Beam Therapeutics vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
Beam Therapeutics is developing base editing technology as a potentially safer next-generation approach to gene correction, while CRISPR Therapeutics has already achieved the historic milestone of the world's first approved CRISPR therapy (Casgevy) with Vertex. CRSP has first-mover approval advantage; BEAM has a potentially safer technology platform that is still earlier-stage.
BEAM vs CRSP is next-generation base editing technology versus proven CRISPR therapy approval — CRISPR Therapeutics has validated the gene editing platform with Casgevy; Beam bets that base editing's precision will win in larger patient populations once clinical proof of concept is established.
BEAM holds the edge across 3 of 5 key metrics in this comparison. BEAM leads on both 1-year return (-9.05%) and forward P/E quality (-5.06x vs -16.10x for CRSP), a relatively favorable combination of momentum and valuation. CRSP leads on both revenue growth (1041.40%) and operating margin (-1127.55%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BEAM (+117.40%) than for CRSP (+55.54%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- believe base editing's precision and safety profile will surpass traditional CRISPR for broader patient populations
- want earlier-stage genetic medicine exposure with higher risk and potential return
- value Broad Institute licensing and David Liu's foundational base editing science
- are comfortable with pre-approval clinical risk across multiple editing programs
- prefer an approved CRISPR therapy with Casgevy generating commercial milestone and royalty revenue
- value Vertex's commercial partnership for Casgevy as a risk-reducing structure
- want gene editing exposure with at least one approved therapy de-risking the platform
- are comfortable with hemoglobinopathy market limitations and CRSP's pipeline diversification risk
| Metric | BEAM | CRSP |
|---|---|---|
| AI scorei | 30.4 | 44.5 |
| AI ranki | #2170 | #743 |
| Latest closei | $24.73 | $51.52 |
| 1M returni | +6.50% | -0.60% |
| 3M returni | -12.89% | +6.07% |
| 6M returni | -18.46% | -7.54% |
| 1Y returni | -9.05% | -28.27% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BEAM | CRSP |
|---|---|---|
| 1Y ago | $9.1K (-9.0%) started 2025-10-15 | $7.17K (-28.3%) started 2025-10-15 |
| 5Y ago | $2.66K (-73.4%) started 2021-10-15 | $5.31K (-46.9%) started 2021-10-15 |
| 10Y ago | $13.19K (+31.9%) started 2020-02-06 | $36.56K (+265.6%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BEAM | CRSP |
|---|---|---|
| Market capi | $2.48B | $5.44B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -5.06 | -16.10 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 9.56 | 292.23 |
| Analyst targeti | $52.15 | $87.56 |
| Target upsidei | +117.40% | +55.54% |
| Metric | BEAM | CRSP |
|---|---|---|
| Revenue growthi | -94.20% | 1041.40% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | -154.99% | -1611.75% |
| Operating margini | -25827.14% | -1127.55% |
| Profit margini | -55.45% | 0.00% |
| ROIC proxyi | -8.18% | -26.10% |
| Return on equityi | -8.18% | -26.10% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 2.23 | 1.74 |
| Debt/equityi | 23.17 | 44.87 |
| Current ratioi | 14.57 | 17.85 |
| Quick ratioi | 14.25 | 17.79 |
Over the past year, BEAM and CRSP have moved strongly in the same direction (correlation of 0.76), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BEAM | CRSP |
|---|---|---|---|
| 1Y | Growthi | -9.05% | -28.27% |
| CAGRi | -9.05% | -28.28% | |
| Volatilityi | 72.68% | 58.20% | |
| Sharpe ratioi | 0.16 | -0.36 | |
| Sortino ratioi | 0.26 | -0.53 | |
| Max drawdowni | 39.08% | 40.06% | |
| Current drawdowni | 34.78% | 30.35% | |
| Avg drawdowni | 20.23% | 26.77% | |
| Ulcer Indexi | 22.63% | 27.56% | |
| Max daily dropi | 10.48% | 11.59% | |
| Max wkly dropi | 20.74% | 18.19% | |
| 5Y | Growthi | -73.45% | -46.89% |
| CAGRi | -23.30% | -11.89% | |
| Volatilityi | 74.95% | 60.92% | |
| Sharpe ratioi | -0.05 | 0.02 | |
| Sortino ratioi | -0.07 | 0.03 | |
| Max drawdowni | 85.32% | 68.81% | |
| Current drawdowni | 75.04% | 48.61% | |
| Avg drawdowni | 65.17% | 43.89% | |
| Ulcer Indexi | 67.30% | 45.38% | |
| Max daily dropi | 19.32% | 13.32% | |
| Max wkly dropi | 31.25% | 21.49% | |
| 10Y | Growthi | +31.89% | +265.65% |
| CAGRi | +4.23% | +13.86% | |
| Volatilityi | 79.49% | 63.96% | |
| Sharpe ratioi | 0.39 | 0.45 | |
| Sortino ratioi | 0.60 | 0.69 | |
| Max drawdowni | 89.12% | 85.11% | |
| Current drawdowni | 81.49% | 75.47% | |
| Avg drawdowni | 60.83% | 50.09% | |
| Ulcer Indexi | 66.25% | 56.55% | |
| Max daily dropi | 23.42% | 17.10% | |
| Max wkly dropi | 41.11% | 30.47% |
| Category | BEAM | CRSP |
|---|---|---|
| Company | Beam Therapeutics Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Biotechnology company developing base editing medicines that correct disease-causing mutations without making double-strand DNA breaks. Beam's technology is derived from the work of David Liu at the Broad Institute and is viewed as a potentially safer approach than traditional CRISPR. | Gene editing company that co-developed Casgevy (exa-cel), the first approved CRISPR-based therapy for sickle cell disease and beta-thalassemia, with Vertex Pharmaceuticals. CRISPR Therapeutics also has a pipeline in diabetes (CTX112) and oncology. |
| Investor focus | Base editing IND filings and clinical trial advancement, hematology programs (sickle cell, beta-thalassemia), in vivo base editing development, and cash runway. | Casgevy commercial ramp and revenue sharing with Vertex, CTX112 diabetes clinical progress, CAR-T oncology pipeline advancement, and in vivo gene editing development. |
- Base editing technology may offer a safer, more precise approach to gene correction than traditional CRISPR-Cas9 double-strand breaks
- Broad Institute licensing provides access to a world-class genomics IP portfolio
- Strong founding science from David Liu's Harvard lab provides credibility and depth of foundational technology
- Casgevy is the world's first approved CRISPR therapy — a historic milestone that validates the platform and generates commercial revenue
- Vertex partnership provides commercial infrastructure and expertise for Casgevy launch without CRSP incurring full commercial buildout costs
- Strong cash position from Vertex milestone payments provides multi-year runway
- Base editing is earlier-stage than CRISPR's approved therapies — clinical proof of concept is not yet established
- Cash burn in discovery-stage biotech is high relative to current revenue
- CRISPR Therapeutics has an approved therapy (Casgevy) — Beam must demonstrate it can close this competitive gap
- Casgevy's one-time high cost ($2M+) and complex treatment process limit the addressable patient population
- In vivo CRISPR delivery remains challenging — most approved applications require ex vivo cell editing
- Pipeline diversification from hemoglobinopathies into diabetes and oncology requires clinical execution
Compare more than two at a time
This page is a fixed writeup on BEAM and CRSP. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside BEAM and CRSP, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.